Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Auxilium Pharmaceuticals
So what: Preliminary revenue of $61.8 million easily surpassed analyst's expectations of $57 million as the company's drugs gain momentum. In 2011, the company expects Xiaflex to generate revenue of $55 million to $67 million, including $5 million to $7 million from royalties and milestones from Pfizer
Now what: Auxilium is on a roll with positive results from Xiaflex, Auxilium, and Testim leading to worldwide revenue growth of 28.7% in the quarter. Despite all of this growth, the company still isn’t expected to be profitable in 2011, leaving me a little bit skeptical. I’m going to stay away from shares today, hoping for a pullback in the next week and a better entry point into the stock.
Interested in more info on Auxilium Pharmaceuticals? Add it to your watchlist.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.
Pfizer is a Motley Fool Inside Value recommendation. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.